Ultra-Long Acting Insulin Glargine

该项目的目的是使用创新的配方技术来开发具有一致的超长释放曲线的胰岛素产品的概念验证。处方将首先使用体外模型进行验证，然后在相关动物模型中展示超长释放谱。Arecor是一家生物治疗制剂公司，拥有一项技术，能够延长胰岛素的时间作用曲线，同时保持适合商业化的产品稳定性曲线。在至少三分之一的患者中，目前销售的产品的作用时间不到24小时，这增加了严重威胁生命的低血糖发作的风险。一致的、延长的释放曲线将降低低血糖风险，同时反过来提高剂量灵活性，从而改善患者的依从性、健康益处和医疗保健提供者的节省。

The aim of the project is to use innovative formulation technology to develop a proof-ofconceptfor insulin product with a consistent, ultra-long release profile. Formulations will firstbe validated with the use of an in vitro model before demonstrating the ultra-long releaseprofile in a relevant animal model. Arecor is a biotherapeutic formulation company with atechnology that has the ability to elongate the time action profile of insulin whilst maintaininga product stability profile suitable for commercialisation. The duration of action for currentlymarketed products is less than 24 hours in at least a third of patients, which increases the riskof severe life-threatening hypoglycaemic episodes. A consistent, elongated release profile willoffer reduced hypoglycaemic risk, whilst in turn improving dose flexibility resulting inimproved patient compliance, health benefits and savings for the healthcare provider.